EVEREST MED (01952) rose nearly 6% during the trading session. As of the time of writing, the stock was up 5.86%, trading at HKD 40.12, with a turnover of HKD 91.7108 million. On January 4th, data from the drug clinical trial registration and information disclosure platform indicated that EVEREST MED's wholly-owned subsidiary, Everest Medicines (Beijing) Pharmaceutical Technology Co., Ltd., has initiated a Phase I study to evaluate the safety, tolerability, and preliminary efficacy of EVM14 as a monotherapy in selected patients with solid tumors. The primary objective of this trial is to assess the safety and tolerability of EVM14 monotherapy in patients with squamous non-small cell lung cancer and head and neck squamous cell carcinoma, and to determine the recommended Phase II dose (RP2D). Secondary objectives include evaluating its anti-tumor activity. Exploratory goals involve investigating the correlation between biomarker expression and efficacy, and assessing immunogenicity, pharmacokinetics, and anti-drug antibodies. EVM14 injection is a biological product intended for the treatment of patients with squamous non-small cell lung cancer and head and neck squamous cell carcinoma. Squamous non-small cell lung cancer is a common type of lung cancer, with symptoms including cough and hemoptysis, diagnosed through imaging and pathology; head and neck squamous cell carcinoma often originates from the mucosa, presenting as ulcers or masses, and can be diagnosed via pathological examination.